Indian pharma firms likely to benefit from MPP-Gilead pact on HIV drug

摘要

Drugmakers in India and China will be able to develop generically similar versions of teno-fovir alafenamide (TAF), a HIV drug undergoing its final stages of testing on humans. The development follows a new licensing agreement between the Medicines Patent Pool (MPP) and the US-based Gilead Sciences on the drug. The announcement was made at the AIDS 2014 conference in Melbourne recently.